RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds

TEL AVIV, ISRAEL & RALEIGH, N.C., July 21, 2023 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale…

Leave a Reply

Your email address will not be published. Required fields are marked *